JasonMHafronMDru

Minimally Invasive Surgery, Surgical Oncology

Professor of Urology at the William Beaumont School of Medicine Chief Medical Officer Director of Clinical Research Michigan Instiute of Urologyiii

Join to view full profile

Dr. Hafron is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hafron's full profile

Already have an account?

Office
6900 Orchard Lake Rd
Ste 101
West Bloomfield, MI 48322
Phone+1 248-539-9036

Fax+1 248-539-9267
Is this information wrong?

Summary

Dr. Jason Hafron is an urologist in West Bloomfield, MI and is affiliated with multiple hospitals in the area, including Beaumont Hospital - Royal Oak and Beaumont Hospital - Troy. He received his medical degree from Loyola University Chicago Stritch School of Medicine and has been in practice 17 years. He specializes in minimally invasive surgery and surgical oncology and is experienced in small cell carcinoma of the kidney, prostate cancer, gynecologic oncology, urologic oncology, and minimally invasive urologic surgery.

Education & Training

Cleveland Clinic FoundationFellowship, Minimally Invasive Urologic Surgery, 2007
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Urology, 2002 - 2006
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Surgery, 2001 - 2002
Loyola University Chicago Stritch School of MedicineClass of 2000

Certifications & Licensure

MI State Medical License 2007 - 2026
OH State Medical License 2006 - 2008
NY State Medical License 2002 - 2004
American Board of Urology Urology

Clinical Trials

A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma Start of enrollment: 2009 Sep 01
Terminated
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
Terminated
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis Start of enrollment: 2020 Oct 01
Completed
Phase 2
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Active, not recruiting
Phase 3
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer Start of enrollment: 2021 Jul 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

Comparison of Polymerase Chain Reaction and Urine Culture in the Evaluation of Patients with Complex Urinary Tract Infections.
Deepak A Kapoor, Rima Aljundi, Bernadette Zwaans, Mitchell Hollander, Mara R Holton, Jason Hafron> ;Biology. 2024 Apr 13
Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
Hafron, J., Crawford, E., Garnick, M.> ;The Journal of Urology. 2024 Mar 1
Reply by Authors.
Hafron, J. M., E David Crawford, Marc B Garnick, Robert H Eckel, Martin M Miner, Stephen J Freedland, Russell K Pachynski, Richard J Wassersug, Matthew T Rosenberg, La...> ;Urology Practice. 2024 Jan 1
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study.
Jason Hafron, Shreyas Joshi, Christopher Smith, Melissa R Kaufman, Janet Okonski, Michael B Chancellor, Breyer, B. N., Breyer, B. N., Hafron, J. M., Benjamin N Breyer> ;International Urology and Nephrology. 2024 Jan 1
A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group.
E David Crawford, Marc B Garnick, Robert H Eckel, Martin M Miner, Stephen J Freedland, Russell K Pachynski, Richard J Wassersug, Matthew T Rosenberg, Lauren M Walker, ...> ;Urology Practice. 2024 Jan 1
Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
Van Neste, L., Henao, R., Wojno, K., Signes, J., DeHart, J., Busta, A., Marriott, E., Willing, M., Argentini, A., Hurley, P., Korman, H., Hafron, J., Putzi, M., Pieczo...> ;The Journal of Urology. 2024 Mar 1
2 citations
Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
E David Crawford, Jason M Hafron, Frans Debruyne, Christopher Wallis, Steven Chang, Marc B Garnick> ;The Journal of Urology. 2024 Jan 1
Clear cell renal cell carcinoma cells show diffuse expression of phagocytotic markers through the identification of lysosome-rich eosinophilic granules.
Vasudevan D Mahalingam, Oumaima S Chaib, Hassan D Kanaan, Jason M Hafron, Ping L Zhang> ;International Urology and Nephrology. 2024 Feb 1
4 citations
Proteogenomic insights suggest druggable pathways in endometrial carcinoma.
Hafron, J. M., Yongchao Dou, Lizabeth Katsnelson, Marina A Gritsenko, Yingwei Hu, Boris Reva, Runyu Hong, Yi-Ting Wang, Iga Kolodziejczak, Rita Jui-Hsien Lu, Chia-Feng...> ;Cancer Cell. 2023 Sep 11
1 citations
Adherence to Hormonal Therapies in Prostate Cancer.
Jason Hafron, Parjosh Sangha, Tiffany Kung, Janis Pruett> ;Urology Practice. 2023 Nov 1
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
Emmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, Lawrence I Karsh, David I Quinn, Jason M Hafron, Helen M Wilfehrt, Matthew Harmon, Nadeem A Sheikh, N...> ;Clinical Cancer Research. 2023 Jul 5
Reply by Authors.
Mark D Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir, Rian J Dickstein, Félix Guerrero-Ramos, Kristen R Scarpato, Jason M Hafron, Edward M Messing...> ;The Journal of Urology. 2023 May 1
1 citations
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phas...
Mark D Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir, Rian J Dickstein, Félix Guerrero-Ramos, Kristen R Scarpato, Jason M Hafron, Edward M Messing...> ;The Journal of Urology. 2023 May 1
Cost-effectiveness of routine type and screens in select urological surgeries.
Joshua Volin, Joshua Daniel, Brianna Walter, Patrick Herndon, Deanna Tran, James Blumline, Aviv Spillinger, Patrick Karabon, Craig Fletcher, Adam Folbe, Jason Hafron> ;International Urology and Nephrology. 2023 Apr 1
6 citations
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Kim N Chi, Neil Fleshner, Vincenzo Emanuele Chiuri, Siska Van Bruwaene, Jason Hafron, Douglas G McNeel, Peter De Porre, Raymond Scott Maul, Mahesh Daksh, Xiaogang Zhon...> ;The Oncologist. 2023 May 8
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Franci...> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023-03-23
IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study.
Jason M Scovell, Mark Stovsky, Alan Partin, Yair Lotan, Jack Baniel, Martin Dineen, Jason Hafron, Kannan Manickam, Marc Pliskin, Matthew Wagner, Aimee Kestranek, Eric ...> ;Urology. 2023 May 1
2 citations
Impact of the bladder detrusor muscular ring on lower urinary tract symptoms due to benign prostatic hyperplasia: A quantitative MRI analysis.
Kiran R Nandalur, David Walker, Hong Ye, Sayf Al-Katib, Brian Seifman, David Gangwish, Abhay Dhaliwal, Ervin Connor, Kayla Dobies, Channing Sesoko, Wesley Dejoie, Bern...> ;The Prostate. 2023 Feb 1
Prevalence and Causes of Discontinuation of Androgen Receptor Inhibitors in Advanced Prostate Cancer Patients and Analysis of Physician Management to Increase Duration...
David Gangwish, Bernadette M M Zwaans, Paul Miriani, Wesley Dejoie, Andrina Ajo, Connor Ervin, Jeff Sarazin, Jason Hafron> ;Urology. 2023 Mar 1
Mammalian Target of Rapamycin (mTOR) Pathway Is Critical in Developing Most Renal Cell Tumors.
Kevin J Zhang, Zhenhong Qu, Elan Pszenica, Jason M Hafron, Ping L Zhang, Robert E Brown> ;Annals of Clinical and Laboratory Science. 2023 Jan 1
Normal Tissue Integral Dose as a Result of Prostate Radiation Therapy: A Quantitative Comparison Between High-Dose-Rate Brachytherapy and Modern External Beam Radiatio...
Vincent P Grzywacz, Jessica D Arden, Nikhil P Mankuzhy, Gary S Gustafson, Evelyn A Sebastian, Veronica L Abbott, Kailee J Walters, Julie A Puzzonia, Amy S Limbacher, J...> ;Advances in Radiation Oncology. 2022 Dec 27
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.
Li Y, Lih TM, Dhanasekaran SM, Mannan R, Chen L, Cieslik M, Wu Y, Lu RJ, Clark DJ, Kołodziejczak I, Hong R, Chen S, Zhao Y, Chugh S, Caravan W, Naser Al Deen N, Hossei...> ;Cancer cell. 2022-12-22
3 citations
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Gordon Brown, Laurence Belkoff, Jason M Hafron, Daniel R Saltzstein, Rushikesh Potdar, Amitabha Bhaumik, Jennifer Phillips, Tracy McGowan, Neal D Shore> ;Targeted Oncology. 2023 Jan 1
4 citations
Adherence With Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences With a Focus on Prostate Cancer.
Celestia S Higano, Jason Hafron> ;The Journal of Urology. 2023 Mar 1
74 citations
Is a 1-CM margin necessary during nephron-sparing surgery for renal cell carcinoma?
Natania Y. Piper, Jay T. Bishoff, Christopher Magee, Jason M Haffron, Robert C. Flanigan, Annemieke Mintiens, Hein Van Poppel, Ian M. Thompson, William J. Harmon> ;Urology. 2001 Dec 1
Join now to see all

Journal Articles

Twelve-Month Prostate Volume Reduction After MRI-Guided Transurethral Ultrasound Ablation of the Prostate
Jason Hafron, MD, European Radiology

Press Mentions

Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological AssociationMarch 16th, 2023
Variation and Correlation in Postoperative Imaging After Shockwave Lithotripsy and Ureteroscopy by Treatment Modality: Results of a Statewide Clinical RegistryOctober 1st, 2022
IsoPSA Shows Notable Diagnostic Accuracy in Detecting Prostate CancerJuly 20th, 2022
Join now to see all